Cargando…

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults

BACKGROUND: Telavancin (TLV) is an advanced generation lipoglycopeptide with activity against methicillin-resistant Staphylococcus aureus (MRSA), but there are limited patient outcomes in the setting of cystic fibrosis pulmonary exacerbation (CFPE). The study objective was to compare the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shorman, Mahmoud, wadi, ghassan, Veve, Michael P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644835/ http://dx.doi.org/10.1093/ofid/ofab466.1515

Ejemplares similares

1315. Ceftaroline Versus Vancomycin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis in Adults
por: Esquivel, Marc, et al.
Publicado: (2021)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

2226. Trough- Versus AUC-Based Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients
por: Smith, Darrell, et al.
Publicado: (2023)

1323. Substantial Doses of Daptomycin and Rifampin Eradicate S. epidermidis Biofilm in an In Vitro Pharmacodynamic (IVPD) Model
por: Piehl, Emily C, et al.
Publicado: (2020)

487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis
por: Brickel, K., et al.
Publicado: (2022)

Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
por: Rodriguez, George D, et al.
Publicado: (2017)

Long-term vancomycin use had low risk of ototoxicity
por: Humphrey, Clayton, et al.
Publicado: (2019)

P1323: THE PROGNOSIS AND COMPLICATIONS OF PATIENTS WITH PRE-TRANSPLANT LIVER DYSFUNCTION
por: Misaki, Yukiko, et al.
Publicado: (2023)

1323. Clinic-Level Factors Associated with Antiretroviral Prescription Rates
por: Hayes, Craig P, et al.
Publicado: (2019)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

1160. Ecological Study for Pulmonary Blastomycosis
por: Wang, James L, et al.
Publicado: (2020)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Vancomycin Safety Monitoring Using an Electronic Health Record Database
por: Veve, Michael P, et al.
Publicado: (2017)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

1323. Implementation and Effectiveness of the Asia Pacific HIV Practice Course: Building Capacity of Healthcare Workers in the Region
por: Michaels, Jessica, et al.
Publicado: (2018)

250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey
por: Dagenais, R., et al.
Publicado: (2022)

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
por: Polyzos, Konstantinos A., et al.
Publicado: (2012)

Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations
por: Merjaneh, Lina, et al.
Publicado: (2020)

1151. Candida Colonization Alters Pathogenic Pulmonary Infection in Pediatric Patients with Cystic Fibrosis
por: Parsons, Emily, et al.
Publicado: (2020)

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
por: Roch, Melanie, et al.
Publicado: (2018)

881. Efficacy of Antibiotic Prophylaxis with Vancomycin in Cardiothoracic Surgery
por: Cooper, Margaret, et al.
Publicado: (2020)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
por: Wojsyk-Banaszak, I., et al.
Publicado: (2019)

Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
por: Hassanzad, Maryam, et al.
Publicado: (2021)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
por: Baranwal, A., et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?
por: Chuan, Junlan, et al.
Publicado: (2016)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

Glucose Tolerance during Pulmonary Exacerbations in Children with Cystic Fibrosis
por: Widger, John, et al.
Publicado: (2012)

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
por: DiMango, Emily, et al.
Publicado: (2014)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
por: Skolnik, Kate, et al.
Publicado: (2018)

Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis
por: Asner, Sandra, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rdmrlvlsec102270etmmsa25a0